<--- Back to Details
First PageDocument Content
Cancer screening / Non-small-cell lung carcinoma / Cancer / Metastasis / Combined small-cell lung carcinoma / Prostate cancer / Medicine / Oncology / Lung cancer
Date: 2013-05-31 14:24:50
Cancer screening
Non-small-cell lung carcinoma
Cancer
Metastasis
Combined small-cell lung carcinoma
Prostate cancer
Medicine
Oncology
Lung cancer

THE UNIVERSITY OF ILLINOIS HOSPITAL & HEALTH SCIENCES SYSTEM: Robert A. Winn Professor of Medicine Associate Vice President for Health Affairs, CBP Director of Lung Cancer Program

Add to Reading List

Source URL: preventcancer.org

Download Document from Source Website

File Size: 1,32 MB

Share Document on Facebook

Similar Documents

CE Objectives and Evaluation Form appear on pageAn Overview of Lung Cancer Symptoms, Pathophysiology, And Treatment Linda H. Yoder

CE Objectives and Evaluation Form appear on pageAn Overview of Lung Cancer Symptoms, Pathophysiology, And Treatment Linda H. Yoder

DocID: 1q0LE - View Document

ZAI Lab announces a global licensing agreement with Sanofi for a novel compound to potentially treat NSCLC ShanghaiZAI Lab Limited (ZAI Lab), an innovative biotech company based in China, announced today

ZAI Lab announces a global licensing agreement with Sanofi for a novel compound to potentially treat NSCLC ShanghaiZAI Lab Limited (ZAI Lab), an innovative biotech company based in China, announced today

DocID: 1kZJy - View Document

DOI:http://dx.doi.orgAPJCPFrequency of EGFR Mutations in Non-small Cell Lung Cancer Patients: Screening Data from West Siberia RESEARCH ARTICLE Frequency of EGFR Mutations in Non-small Cell Lung C

DOI:http://dx.doi.orgAPJCPFrequency of EGFR Mutations in Non-small Cell Lung Cancer Patients: Screening Data from West Siberia RESEARCH ARTICLE Frequency of EGFR Mutations in Non-small Cell Lung C

DocID: 1g8iz - View Document

Axelar announces final data from Phase II study with AXL1717 in lung cancer STOCKHOLM, SWEDEN – December 27, 2013. Axelar AB announced today the final results from its Phase II study AXL-003 in patients with non-small

Axelar announces final data from Phase II study with AXL1717 in lung cancer STOCKHOLM, SWEDEN – December 27, 2013. Axelar AB announced today the final results from its Phase II study AXL-003 in patients with non-small

DocID: 1axZw - View Document

Thoracic Oncology Introduction Research Activities  The Division of Thoracic Oncology cares for

Thoracic Oncology Introduction Research Activities The Division of Thoracic Oncology cares for

DocID: 1ao47 - View Document